# US 2003/0229913 A1 · Identification of the flt1 gene required for angiogenesis in zebrafish and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229913 A1
- Document ID: US20030229913A1
- Status: Published application
- Kind: A1
- Application number: 10/402,365
- Filed: 2003-03-27
- Published: 2003-12-11
- Earliest claimed: 2002-03-27
- Inventors: Hinrich Alexander Habeck; Stefan Schulte-Merker
- Web page: https://patentgrep.com/patent/US20030229913A1

## CPC

- C12N 15/1138: {against receptors or cell surface proteins}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- C07K 14/71: for growth factors; for growth regulators
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/40: Fish
- A01K 2267/03: Animal model, e.g. for test or diseases
- C12N 2310/314: Phosphoramidates
- C12N 2310/3233: Morpholino-type ring
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

An engineered mutant teleost embryo having reduced flt1 activity that causes a phenotype of normal assembly of main circulatory routes and a reduction in sprouted blood vessels is described. Methods of using the mutant teleost embryo for identifying genes that interact with flt1 are also described.

## Claims

### Claim 1

An engineered mutant teleost embryo having reduced flt1 activity that causes a phenotype of normal assembly of main circulatory routes and a reduction in sprouted blood vessels.

### Claim 2 (depends on 1)

The teleost embryo of claim 1 that is a homozygous carrier of an induced mutation of flt1.

### Claim 3 (depends on 1)

The teleost embryo of claim 1 that contains an exogenously added nucleic acid inhibitor that specifically inhibits flt1.

### Claim 4 (depends on 3)

The teleost embryo of claim 3 wherein the exogenously added nucleic acid inhibitor is an antisense phosphoramidate morpholino (PMO).

### Claim 5 (depends on 1)

The teleost embryo of claim 1 that is a zebrafish.

### Claim 6

A method for identifying a gene that interacts with flt1 comprising:
a) crossing a teleost that is a heterozygous carrier of an induced mutation of flt1 with a second teleost that is a heterozygous carrier of an induced mutation in a gene of interest to generate doubly heterozygous progeny that are heterozygous carriers of the induced mutation in flt1 and of the induced mutation in the gene of interest, and
b) examining vasculature of the doubly heterozygous progeny, wherein a double heterozygote that displays a vascular defect phenotype identifies the gene of interest as a gene that interacts with flt1.

### Claim 7 (depends on 6)

The method of claim 6 wherein the induced mutation in the gene of interest is targeted.

### Claim 8 (depends on 6)

The method of claim 6 wherein the induced mutation in the gene of interest is random.

### Claim 9

A method of identifying a gene that interacts with flt1 comprising:
a) crossing teleosts that are heterozygous carriers of an induced mutation of flt1, to generate fertilized eggs;
b) injecting the fertilized eggs with a nucleic acid inhibitor that specifically inhibits a gene of interest;
c) culturing the eggs under conditions that allow formation of teleost embryos, and
d) examining vasculature of the teleost embryos;
wherein the gene of interest is identified as a gene that interacts with flt1 if the percentage of teleost embryos that exhibit an flt1 phenotype is significantly higher or lower than 25%.

### Claim 10 (depends on 9)

The method of claim 9 wherein the molecule is a PMO.

### Claim 11

A method for identifying a gene that interacts with flt1 comprising:
a) injecting a flt1 PMO together with a PMO directed to a gene of interest into wild-type teleost eggs,
b) culturing the eggs under conditions that allow formation of teleost embryos, and
c) examining vasculature of the teleost embryos,
wherein the gene of interest is identified as a gene that interacts with flt1 if the teleost embryos exhibit a phenotype that differs from phenotypes exhibited by single-injection control teleost embryos.

### Claim 12

A method for identifying a gene that interacts with flt1 comprising:
a) injecting a flt1 PMO into teleost eggs derived from a mating of a heterozygous mutant carrier of a defect in a gene of interest with a wildtype teleost,
b) culturing the eggs under conditions that allow formation of teleost embryos, and
c) examining vasculature of the teleost embyos,
wherein the gene of interest is identified as a gene that interacts with flt1 if a more or less severe vascular defect phenotype is observed in 50% of the embryos as compared to a flt1 phenotype.

### Claim 13

A PMO that specifically inactivates a teleost Flt1 gene, said PMO comprising a nucleotide sequence of 10-50 nucleotides that are complementary to contiguous nucleotides within a nucleotide sequence selected from the group consisting of any one of SEQ ID NOs:3-57, and nucleotides 1-400 of SEQ ID NO: 1.

### Claim 14 (depends on 13)

A PMO of claim 13 having a nucleotide sequence complementary to 21 to 25 contiguous nucleotides within nucleotides 1-365 of SEQ ID NO: 1.

### Claim 15 (depends on 13)

A PMO of claim 13 that comprises SEQ ID NO:3.
